AzTrials
AzTrials

Aseptic Necrosis of Femur HeadBMP7NCT02655120

Autologous Bone Marrow and BMP7 Treatment in the Necrosis in the Femoral Head of the Adult

A study testing Drilling and Bone Marrow +BMP7 in people with Aseptic Necrosis of Femur Head, run by University Hospital, Lille at 1 site in France.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The main objective of the study is to evaluate the effectiveness of the injection of bone marrow unconcentrated more R BMP 7 to repair necrosis of the femoral head with stage I-III classification FICAT. Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Aseptic Necrosis of Femur Head
What is being tested?
Drilling and Bone Marrow +BMP7
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
41 participants
Where
1 siteFrance
Study dates
Mar 2005to May 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patient aged between 18 and 60 years male or female.
  • Necrosis of the femoral head stage I to III FICAT (stage III with depression of less than 3 mm)
  • Nontraumatic osteonecrosis
  • Patient can undergo general anesthesia or locoregional
  • Having given his consent
  • Able to understand the constraints of the study

Who cannot join

  • Refusing to participate in the study
  • Active infection at the site
  • Cancer changing
  • Pregnancy
  • Necrosis posttraumatic
  • Having already undergone surgery on the surgical site
Show all 9Show fewer
  • Contraindication to the practice of NMRI
  • Contraindication to the use of OP1 (BMP7): collagen, arthritis, scleroderma, lupus
  • Patient participating in another ongoing study

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHRU de LILLE - service d'orthopédie C

    Lille, 59037

Other trials in France

About this study

Official title: Evaluation of the Efficiency of Autologous Bone Marrow no Concentrated to Associate at BMP7 Treatment of Necrosis of the Femoral Head of the Adult

The main objective of the study is to evaluate the effectiveness of the injection of bone marrow unconcentrated more R BMP 7 to repair necrosis of the femoral head with stage I-III classification FICAT.

Read the detailed description

Rationale and Objectives Epiphyseal necrosis are common in young adults (2000 new cases per year in the Nord Pas -de- Calais region) resulting in severe functional impairment and disability . Drilling is the procedure most simple, but its effectiveness and safety are discussed ( fracture risk , long discharge period , success rates below 50 % until stage III). However, it can be optimized in two ways: 1) reducing morbidity and discharge period by reducing the diameter of the channel and percutaneous achievement , 2 ) increase efficiency , including coverage contribution of stem cells and osteogenic hormone . The purpose of this study is to test the effectiveness of the contribution of these elements to the healing necrosis .

Material, Method, and primary endpoint This is a prospective multicenter clinical trial randomized double-blind . The effect of addition of autologous bone marrow stem cells and BMP7 on healing necrosis is assessed by magnetic resonance imaging ( NMRI ) and is the primary endpoint . Patients are randomly assigned to two arms : 1 ) Group I: a simple drilling is practiced , 2 ) Group II : the drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 ( OP1 ) . Necrosis of the femoral head with stage I to III are retained Ficat (only stage III with a recess of less than 3 mm are used , corresponding I-III according to Steinberg ) . Forty patients are included in each arm . A IRMN practiced preoperatively and at 6 months and 2 years. Clinical evaluation will be continued up to 5 years in testing the survival rate ( criterion censorship = recovery by hip ) Expected results and possible implications In terms of radiological stabilization ( NMRI ) the effectiveness of single drilling necrosis stage I to III Ficat is 60 % ( non- stabilization or worsening of size). The hypothesis tested is a gain stabilization ( and / or recovery) of 20 % . The clinical efficacy of single drilling necrosis stage I to III Ficat is estimated at 50 % (50% recovery by prosthesis in 5 years) . The assumption is a 20% improvement in the rate of success of the intervention . Reducing morbidity due to technical modifications has been previously tested. If the assumption of success is reached, the indications of drilling could be reinforced especially for patients with multiple visceral defects usually supported on the websites of University Hospital of Lille and Amiens and CH Roubaix ( organ transplant or tissue , ethyl , .. ) .

Being tested
Drilling, Bone Marrow +BMP7
Keywords
Femoral head necrosis, Autologous Bone Marrow, BMP7
Medical subject headings
Femur Head Necrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DrillingProcedure or surgery

  • Bone Marrow +BMP7Biological

Study groups in NCT02655120
Study groupRoleWhat they receive
Bone Marrow +BMP7ExperimentalThe drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 (OP1)
Receives: Biological: Bone Marrow +BMP7
DrillingPlacebo comparatorGroup I: a simple drill is practiced
Receives: Procedure: Drilling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Necrosis volume

    Varying the volume of necrosis in MRI, student test comparing the mean (independent samples).

    Measured: 24 months

Secondary outcomes (3)
  1. Merle d'aubigné hip score

    variation of functional score, according to the two groups, by ANOVA repeated measures

    Measured: 6 and 24 months

  2. Measurement of radiographic stage variation between pre-operative and 24 months radiographies using concentric circles of Möse

    Measured: 24 months

  3. Comparison of hip survival by measuring the number of revisions for hip replacement in the 2 groups

    Hip survival (= no revision for hip replacement) will be assessed using Kaplan-Meier curves and Logrank test.

    Measured: 60 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jan 2016 (estimated)
  2. Study startMar 2005
  3. Primary completionMay 2017
  4. Study completionMay 2017

Why it stopped: stopping the marketing of BMP7

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
41 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02655120
Sponsor's protocol ID
2005-0503
Other IDs
TC 183
Acronym
BMP7
Status last verified
May 2018
First submitted
12 Nov 2014
Last updated
8 May 2018
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Drilling and Bone Marrow +BMP7 in people with Aseptic Necrosis of Femur Head, run by University Hospital, Lille at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 8 May 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: stopping the marketing of BMP7). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Necrosis volume (time frame: 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in